A study in a South American medical journal suggests a possible benefit tied to GLP-1 drugs. The teaser leaves out what improved, so tap through for specifics.
Recap by typeshit. Post by ABC 7 Chicago on X.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Engel says the drug caused his total vision loss, and his lawsuit argues Novo Nordisk's warnings were inadequate. He is urging other users to watch for symptoms.
In a SUNY Upstate study shown at ACG 2026, tirzepatide users had the biggest drop. The authors say prospective trials are still needed to prove a protective effect.
Loading…